$918 Million is the total value of Redmile Group, LLC's 54 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | New | GILEAD SCIENCES INC | $34,746,000 | – | 368,615 | +100.0% | 3.78% | – |
| AZN | New | ASTRAZENECA PLCsponsored adr | $18,180,000 | – | 258,305 | +100.0% | 1.98% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS INC | $17,269,000 | – | 860,809 | +100.0% | 1.88% | – |
| BIIB | New | BIOGEN IDEC INC | $14,635,000 | – | 43,113 | +100.0% | 1.59% | – |
| BLUE | New | BLUEBIRD BIO INC | $9,376,000 | – | 102,227 | +100.0% | 1.02% | – |
| NVRO | New | NEVRO CORP | $9,059,000 | – | 234,254 | +100.0% | 0.99% | – |
| CNXR | New | CONNECTURE INC | $8,496,000 | – | 943,000 | +100.0% | 0.92% | – |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $7,069,000 | – | 264,266 | +100.0% | 0.77% | – |
| EBIO | New | ELEVEN BIOTHERAPEUTICS INC | $2,851,000 | – | 240,000 | +100.0% | 0.31% | – |
| New | ARRAY BIOPHARMA INCnote 3.000% 6/0 | $1,869,000 | – | 2,000,000 | +100.0% | 0.20% | – | |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $1,866,000 | – | 237,977 | +100.0% | 0.20% | – |
| FWP | New | FORWARD PHARMA A/Ssponsored adr | $526,000 | – | 25,235 | +100.0% | 0.06% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $476,000 | – | 26,100 | +100.0% | 0.05% | – |
| QQQ | New | POWERSHARES QQQ TRUSTunit ser 1 | $355,000 | – | 3,434 | +100.0% | 0.04% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $257,000 | – | 1,390 | +100.0% | 0.03% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $64,000 | – | 25,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.